Taking stock of the drug industry, from the lab to the medicine chestSeptember 16, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Justin Sullivan/Getty Images STAT+ | Genentech, a biotech with a storied past, confronts new turbulence in the present The closure of the company's cancer immunology group and multiple rounds of layoffs have prompted concern about its future. By Jonathan Wosen STAT+ | After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do The ESMO meeting was an opportunity for many to give thanks for what therapies like Keytruda and Opdivo have achieved, and to consider what comes next. By Andrew Joseph STAT+ | Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending The initial results suggest that Exact's test could be an alternative to others on the market, but the findings come from a small study. By Jonathan Wosen Jeenah Moon/Getty Images STAT+ | Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness The company reported at the annual ESMO meeting that an experimental antibody helped cancer patients with a condition known as cachexia. By Andrew Joseph STAT+ | AstraZeneca's Imfinzi increases survival rates in bladder cancer in pivotal study If the trial design doesn't trigger regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated. By Andrew Joseph More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments